Member Info for Steg

Hi pickled indeed very exciting, really looking forward to the final results especially met clock. Think then we might have a better handle on what we are dealing with. Spot on with the will we won’t we rns from acvim poster it’s just another step on the journey. I am happy to be patient with the stock as it’s going to take time for events to fully unfold but I have a high confidence level. Think maybe patent award is next as Porter highlighted due any time now, just another part of the jigsaw but a super important one for sure 👍

Great find money, the read across and validation of our strategy is potentially excellent news and the valuation prior to human trials is mind boggling 👍

Buy for sure the price would of crashed if someone dumped as much and it didn’t, it went up

Hi pickled she (Genf) is in safe hands as porter mentioned your amongst friends in Bonnie Scotland, I am always available for any gate crashing duties lol. Have a great time and the weather is scheduled to warm up nicely from the end of next week so your timing is good. Bet you have a wee peek when you get WiFi lol all the very best and hope your daughter and partner have a magical day. Hopefully we will have moved on a bit by the time your back and I look forward to your analysis of any breaking news while you away atvb

Another excellent post pp, even though it doesn’t specifically mention Genflow the people that need to know will know in terms of big pharma, sounds like it’s game on with this massive unlock and allows a blockbuster rns from Genflow when the time is right. I wonder how the us would value Genf now, I doubt at the current very low market cap and as this unfolds I don’t think the uk current price at 2p will have much bearing on the potential deal value.

Great information and definitely suggests that factors are in play that the general population of investors aren’t aware of, excited to see what tomorrow brings, feels like a well thought out strateg plan which could evolve into something much bigger I hope

Yes this weeks mar marking on rns suggest Genflow are in receipt of information that’s not been made public yet, could be a lot of things grant, dog results, dog deal, acuitas presentation reveals or a multitude of other things. Clearly I have no idea but I view the tagged rns as positive in light of all the known information so far. Watching for detail on this weeks presentations closely. Next rns should start to give more clarity. We know final dog data is due ifairly soon and hopefully it will be super positive 🤞

Yes offgrid very positive, Eric said worse case big up front way larger than current market cap suggests to me Genflow prefer to sell the dog program outright. Anyone any guesses from fun what we could be looking at for an outright purchase, I would say way way north of 50M 🤞the best thing for me is either kind of deal let’s Eric get on with Ophthalmology Sarcopenia and Glaucoma without any funding worries but will also attract high levels of interest from major pharmaceutical companies although I feel we are well on the radar already

😂 yes done that before, weird how you can’t edit posts on this forum, well that’s very exciting and I guess might encourage a licensing deal which would be massive news especially if it follows a deal on dog program 🤞 thank you for the clarification

Yip just googled the lady and referenced the presentation and that’s what it generated, what’s ng news mean?

Hilda Au, Ph.D., is a Research Scientist at Acuitas Therapeutics who is scheduled to present at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.Conference Presentation DetailsDr. Au will be presenting a poster on Wednesday, 13 May 2026, from 5:00 pm to 6:30 pm.Location: MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level).Context: While the exact title of her poster for 2026 was not explicitly detailed in recent press releases, market analysts have linked her work to the delivery of epigenetic medicines that modulate gene expression without altering DNA—specifically in relation to non-human primate (NHP) liver data.Professional BackgroundRole: She is a scientist specialized in lipid nanoparticle (LNP) delivery systems, the technology that was essential for the Pfizer-BioNTech COVID-19 vaccine.Education: She earned her Ph.D. from the University of British Columbia (2010–2016).Advocacy: Beyond her research, she is recognized as a prominent woman in STEM, often speaking on her experiences as a woman of colour in the biotech industry

1m top up today, been buying and holding for 2 years now. Hope this comes good for everyone. Methylation results patents possible dog deal more grant funding all very likely in the short term, definitely a year of catalysts as Eric said. Also thinking and hoping mash and / or ophthalmology deal by year end, all very exciting gla

Major pharmaceutical companies have increasingly pivoted toward preclinical-stage acquisitions to replenish pipelines ahead of significant patent expirations. Within the last two years (2024–2026), deals for companies yet to enter human trials have often focused on high-growth areas like obesity, immunology, and RNA therapeutics.The following list identifies significant biotech buyouts from mid-2024 through early 2026, specifically for companies that were acquired at a preclinical stage (no human trials started at the time of announcement or closing), ranked by their approximate total potential deal value.Kate Therapeutics: $1.1 billionAcquirer: Novartis (November 2024).Focus: Gene therapies for rare neuromuscular disorders.Trial Status: Entire program portfolio was preclinical at the time of the deal.Aiolos Bio: $1 billion upfront (up to $1.4 billion total)Acquirer: GSK (January 2024).Focus: Asthma and chronic rhinosinusitis treatments.Trial Status: Lead asset AIO-001 was ready for Phase II, but the company's internal platform and additional programs were largely preclinical at the time of the GSK acquisition.Verve Therapeutics: $1 billion upfront (up to $1.3 billion total)Acquirer: Eli Lilly (July 2025).Focus: In-vivo gene-editing programs for cardiovascular disease.Trial Status: Centred around VERVE-102 and other discovery-stage gene-editing bets.Dark Blue Therapeutics: $840 millionAcquirer: Amgen (January 2026).Focus: Small molecule-targeted protein degraders for cancer.Trial Status: Privately held developer of early-stage, preclinical assets.Cardior Pharmaceuticals: €1 billion (approx. $1.1 billion total)Acquirer: Novo Nordisk (March 2024).Focus: RNA-based therapies for heart failure.Trial Status: While lead candidate CDR-132L was entering clinical readiness, the Novo Nordisk deal was largely for the preclinical platform and pipeline.EsoBiotec: Undisclosed Upfront (Estimated $1 billion+ potential)Acquirer: AstraZeneca (2025).Focus: In vivo CAR-T cell therapy.Trial Status: Preclinical stage developer focused on genetic engineering of cells within the body.Cue Biopharma (CUE-501 Program): $357 million (up to)Acquirer: Boehringer Ingelheim (April 2025).Focus: Preclinical bispecific antibody for autoimmune diseases.Trial Status: Acquisition of a single preclinical asset rather than the full company.Abceutics: $208 millionAcquirer: Merck (April 2024).Focus: Specialized payload delivery for antibody-drug conjugates (ADCs).Trial Status: Early-stage biotech acquired for its platform technology.ReNAgade Therapeutics: Acquired by Orna Therapeutics (supported by Vertex)Deal context: Strategic exit in mid-2024.Focus: RNA delivery technology.Trial Status: Entirely preclinical platform at the time of the Orna acquisition.Mablink Bioscience: UndisclosedAcquirer: Eli Lilly (Late 2023/Early 2024).Focus: Next-generation antibody-drug conjugates (ADCs).Trial Status: Explicitly stated as a preclinical biotechnology company at acquisition.

Future Outlook (Assuming Positive Methylation Results)

If Genflow's GF-1002 (SIRT6-based therapy) or its GF-1004 dog ageing study shows significant "reversal" on the methylation clock, its ranking is expected to rise due to several key factors:

Tier-1 Partnerships: Genflow has already entered confidentiality agreements with Tier-1 global animal health companies to review its canine SIRT6 data as of April 2026. Positive efficacy results could trigger major licensing deals.

Clinical Readouts: Initial efficacy data for its canine study is expected in Q1 2026, with further durability results in June-July 2026.

Translation to Human Health: Success in current animal trials is viewed by the company as a critical step toward human applications, which would place it in the same clinical-stage bracket as multibillion-dollar firms like Celularity or Fate Therapeutics

Marty you can relax, just because someone started to make cars and everything else in the world did it stop others from trying to do the same to capture market share. It will come down to consumer choice however if you look at the scale of the top 5 animal health companies you will understand they all have very professional vast sales teams with rellationships with vets across the world Loyal don’t and won’t be able to build this kind of infrastructure So the big guys will absolutely see the market as vast and addressable, loyal might go down the direct toconsumer route but ultimately When your dog needs support who do you go and speak to. Eric will have no say whatever in the international role out strategy.

Of course mm fully understand. Agreed very exciting been in for 2 years now, have had a couple of false starts but this time feels very real. Fairly sure we see dog deal in 2026 and I feel a least one more deal if not more. Love the size of the markets that we could be exposed to, think one really big deal like the dogs will get worldwide press and put Genf on the map as right now clearly we are way under the radar, good for those trying to accumulate a few more I guess 😉

Hi troops we have a telegram group with major external shareholders of the company. it’s been opened up today if anyone wants to join, everyone is welcome PP and MM would be great if you guys were able to join but everyone is welcome. Genflow Bio is the search name

An excellent well thought out and thought provoking post, feel free to finish it if you have the notion, I was really enjoying readings, got to say I agree with everything you have said and have also backed heavily over the last 2 years, I feel your absolutely right about gaining traction in the uk. Think we need blockbuster news like a major deal on the dogs to gain many more eyes on Genflow around the world, let’s be honest very few people know anything if the company, when this changes so will the share price, now where’s the blockbuster news? Confident it will come in 2026 and maybe quite soon gla

Unless time frame has slipped due for news this week 🤞🤞🤞it could be big if the dog results are good

**** poor grammar apologies hopefully you can work out my garble lol :)